Numinus Announces Key Milestones in MAPS-Sponsored MDMA-Assisted Therapy for PTSD Clinical Trial Jan 19, 2022
Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product Jan 14, 2022
How Significant Are Recent Changes To Psychedelics Access In Canada? ‘It Can’t Be Understated’ Says Numinus CEO Jan 12, 2022
What Health Canada’s New Special Access Program Amendments Mean For Medical Access To Psychedelics Dec 23, 2021
